<DOC>
	<DOCNO>NCT00457015</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety DX-88 ( ecallantide ) versus placebo treatment moderate severe acute attack hereditary angioedema .</brief_summary>
	<brief_title>Efficacy Study DX-88 ( Ecallantide ) Treat Acute Attacks Hereditary Angioedema ( HAE )</brief_title>
	<detailed_description>This randomize placebo-controlled trial . The study design assess efficacy safety 30 mg subcutaneous ecallantide versus placebo treatment moderate severe acute attack hereditary angioedema . This study conduct Special Protocol Assessment FDA design provide pivotal efficacy data ecallantide . These data intend support marketing authorization ecallantide treatment acute attack hereditary angioedema . Efficacy safety ecallantide evaluate study .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>10 year age older Executed inform consent Documented diagnosis HAE ( Type I II ) Presentation site within 8 hour patient recognition moderate severe HAE acute attack Receipt investigational drug device , within 30 day prior study treatment Receipt noninvestigational C1INH within 7 day treatment Receipt DX88 ( ecallantide ) within 3 day prior study treatment Diagnosis acquire angioedema ( AAE ) , estrogendependent angioedema druginduced angioedema ( include angiotensinconverting enzyme inhibitor induce angioedema ) Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>